Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-11

Clinical Trial Update: A Phase II Study of BVD-523 in Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase II study of BVD-523 in metastatic uveal melanoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BVD-523

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Uveal Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2021-11-11